Emergent BioSolutions (EBS) Other financing activities (2010 - 2025)

Emergent BioSolutions' Other financing activities history runs 16 years deep, the most recent figure standing at -$800000.0 for Q3 2025.

• On a quarterly basis, Other financing activities changed N/A year-over-year to -$800000.0 in Q3 2025; TTM through Mar 2026 was -$100000.0, a 100.74% decrease from a year earlier, with the FY2024 full-year figure at $13.4 million, changed N/A from the prior year.
• Other financing activities fell to -$800000.0 in Q3 2025 per EBS's latest filing, from $700000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $12.7 million in Q4 2024 and bottomed at -$3.0 million in Q4 2022.
• The 5-year median for Other financing activities is $1.0 million (2023), against an average of $2.1 million.
• Across the five-year window, Other financing activities plunged 188.24% in 2022 and changed 0.0% in 2025, its largest moves.
• Year by year, Other financing activities stood at $3.4 million in 2021, then plunged by 188.24% to -$3.0 million in 2022, then surged by 56.67% to -$1.3 million in 2023, then jumped by 1076.92% to $12.7 million in 2024, then slumped by 106.3% to -$800000.0 in 2025.
• Per Business Quant, the three latest EBS Other financing activities figures stand at -$800000.0 (Q3 2025), $700000.0 (Q2 2025), and $100000.0 (Q1 2025).